Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 2;11(11):2139-2145.
doi: 10.1021/acsmedchemlett.0c00215. eCollection 2020 Nov 12.

Vinyl Sulfone-Based Inhibitors of Nonstructural Protein 2 Block the Replication of Venezuelan Equine Encephalitis Virus

Affiliations

Vinyl Sulfone-Based Inhibitors of Nonstructural Protein 2 Block the Replication of Venezuelan Equine Encephalitis Virus

Huaisheng Zhang et al. ACS Med Chem Lett. .

Abstract

Emerging infectious diseases like those caused by arboviruses such as Venezuelan equine encephalitis virus (VEEV) pose a serious threat to public health systems. Development of medical countermeasures against emerging infectious diseases are of utmost importance. In this work, an acrylate and vinyl sulfone-based chemical series was investigated as promising starting scaffolds against VEEV and as inhibitors of the cysteine protease domain of VEEV's nonstructural protein 2 (nsP2). Primary screen and dose response studies were performed to evaluate the potency and cytotoxicity of the compounds. The results provide structural insights into a new class of potent nonpeptidic covalent inhibitors of nsP2 cysteine protease represented by compound 11 (VEEV TrD, EC50 = 2.4 μM (HeLa), 1.6 μM (Vero E6)). These results may facilitate the evolution of the compounds into selective and broad-spectrum anti-alphaviral drug leads.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Scheme 1
Scheme 1. Synthesis of Target Compounds 116
Reagents and conditions: (a) CH2Cl2:CH3OH, Et3N, Boc2O, 23°C, 2 h, > 90%; (b) H2O, NaIO4, RT, 1 h, 64%; (c) NaH, THF, methyl diethylphosphonoacetate, diethyl((methylsulfonyl)methyl) phosphonate or diethyl((phenylsulfonyl)methyl) phosphonate, 0°C, 25 min, 40–70%; (d) 33% TFA in DCM, 0°C, 1.5 h. Then ACN, R-COOH, Et3N, HBTU, RT, 16 h, 30-40%; (e) DMP, H2O–DCM, 23 °C, 1 h, 40–60%.
Figure 1
Figure 1
Inhibition of VEEV nsP2 protease by compounds 12 and 13 in a gel discontinuous assay. V12: CFP-YFP FRET substrate; nsP2: tag-free nonstructural protease 2. For both gels, Lane 1 is V12 alone, Lane 2 is V12 + nsP2, Lanes 3–10 are V12 + nsP2 + 12 or 13 at 3.6, 1.8, 0.9, 0.45, 0.22, 0.11, 0.06, and 0.03 μM, respectively. The molecular weights (MW) of uncut V12, the two V12 fragments (cut v12), and tag-free nsP2 are 58.3, 30.9, 27.4, and 38.29 kDa, respectively. The reactions were carried out in 50 mM HEPES buffer pH 7.4 for 24 h at room temperature. The concentrations of VEEV nsP2 and V12 were 1 μM and 10 μM, respectively.
Figure 2
Figure 2
Modeled complex of VEEV nsP2 and compound 11. The highlighted residues are predicted to have significant van der Waals interactions (piecewise linear potential) with compound 11. The blue dash depicts H-bond interaction. The figure was prepared using Molecular Operating Environment (MOE).
Figure 3
Figure 3
Modeled complex of VEEV nsP2 and compound 11. The left panel is a stick model representation of the predicted network of H-bond interactions (depicted as the blue dash lines) stabilizing the nsP2–11 complex. Asn 545, His 510, and His 546 residues are predicted to have direct H-bond interactions with compound 11. Carbon atoms are depicted as yellow in 11. The right panel is a 2D depiction of the proximity (gray contour) of active site residues to compound 11 as well as the extent of exposure (purple hue) of the compound’s atoms to solvent. The figure was prepared using Molecular Operating Environment (MOE).

Similar articles

Cited by

References

    1. Aguilar P. V.; Estrada-Franco J. G.; Navarro-Lopez R.; Ferro C.; Haddow A. D.; Weaver S. C. Endemic Venezuelan equine encephalitis in the Americas: hidden under the dengue umbrella. Future Virol. 2011, 6, 721–740. 10.2217/fvl.11.50. - DOI - PMC - PubMed
    1. Sharma A.; Knollmann-Ritschel B. Current understanding of the molecular basis of Venezuelan equine encephalitis virus pathogenesis and vaccine development. Viruses 2019, 11, 164.10.3390/v11020164. - DOI - PMC - PubMed
    1. Carrera J. P.; Bagamian K. H.; Travassos da Rosa A. P.; Wang E.; Beltran D.; Gundaker N. D.; Armien B.; Arroyo G.; Sosa N.; Pascale J. M.; Valderrama A.; Tesh R. B.; Vittor A. Y.; Weaver S. C. Human and equine infection with alphaviruses and flaviviruses in Panamá during 2010: a cross-sectional study of household contacts during an encephalitis outbreak. Am. J. Trop. Med. Hyg. 2018, 98, 1798–1804. 10.4269/ajtmh.17-0679. - DOI - PMC - PubMed
    1. Zacks M. A.; Paessler S. Encephalitic alphaviruses. Vet. Microbiol. 2010, 140, 281–286. 10.1016/j.vetmic.2009.08.023. - DOI - PMC - PubMed
    1. Reichert E.; Clase A.; Bacetty A.; Larsen J. Alphavirus antiviral drug development: scientific gap analysis and prospective research areas. Biosecur. Bioterror. 2009, 7, 413–427. 10.1089/bsp.2009.0032. - DOI - PubMed